Aspirin resistance: Clinical significance and genetic polymorphism

Journal of International Medical Research

Volumn 40, Issue 1, 2012, Pages 282-292

  Xu, Z H ^a   Jiao, J R ^a   Yang, R ^a   Luo, B Y ^a   Wang, X F ^a   Wu, Fang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Antiplatelet agent; Aspirin resistance; Genetic polymorphism; Platelet aggregation tests; Prostaglandin endoperoxide synthase 1 (PTGS1); PTGS2

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; ASPIRIN RESISTANCE; CHINESE; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; INTEGRIN BETA3 GENE; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PREVALENCE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 1 GENE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2 GENE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY;

EID: 84863266046     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000128     Document Type: Article

References (35)

1. Undas A, Brummel-Ziedins KE, Mann KG: Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109: 2285-2292.
2. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
3. Szczeklik A: Reasons for aspirin resistance. Thromb Haemost 2011; 105: 1124.
4. Patrono C, García Rodríguez LA, Landolfi R, et al: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
5. Ajzenberg N, Aubry P, Huisse MG, et al: Enhanced shear induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. Am Coll Cardiol 2005; 45: 1753-1756.
6. Kenichi F, Yoshio K, Hideki K, et al: Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. Circ J 2008; 72: 1282-1284.
7. Eikelboom JW, Hirsh J, Weitz JI, et al: Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
8. Voora D, Horton J, Shah SH, et al: Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. Am Heart J 2011; 162: 166. e1-172. e1.
9. Goodman T, Ferro A, Sharma P: Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-232.
10. Papp E, Havasi V, Bene J, et al: Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005; 39: 1013-1018.
11. Dropinski J, Musial J, Sanak M, et al: Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res 2007; 119: 301-303.
12. Sanderson S, Emery J, Baglin T, et al: Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-380.
13. Carroll RC, Worthington RE, Craft RM, et al: Post interventional cardiology urinary thromboxane correlates with platelet mapping detected aspirin resistance. Thromb Res 2010; 125: e118-22.
14. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46: 1705-1709.
15. Macchi L, Sorel N, Christiaens L: Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des 2006; 12: 251-258.
16. Shantsila E, Watson T, Lip GY: Aspirin resistance: what, why and when? Thromb Res 2007; 119: 551-554.
17. Poulsen TS, Jørgensen B, Korsholm L, et al: Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007; 119: 555-562.
18. Ferguson AD, Dokainish H, Lakkis N: Aspirin and clopidogrel response variability. Tex Heart Inst J 2008; 35: 313-320.
19. Harrison P: Platelet function analysis. Blood Rev 2005; 19: 111-123.
20. Renda G, Zurro M, Malatesta G, et al: Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010; 95: 2095-2101.
21. Montagnana M, Fava C, Arosio E, et al: Inflammation and platelet activation in peripheral arterial occlusive disease. Int J Angiol 2007; 16: 84-88.
22. Bruno A, McConnell JP, Cohen SN, et al: Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke 2004; 35: 727-730.
23. Lordkipanidzé M, Pharand C, Schampaert E, et al: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
24. Barone-Rochette G, Ormezzano O, Polack B, et al: Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases. Arch Cardiovasc Dis 2008; 101: 100-107.
25. Flaherty MP, Johnston PV, Rade JJ: Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel. J Invasive Cardiol 2011; 23: 300-304.
26. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-654.
27. Maree AO, Curtin RJ, Chubb A, et al: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.
28. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-130.
29. Hillarp A, Palmqvist B, Lethagen S, et al: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003; 112: 275-283.
30. Takahashi S, Ushida M, Komine R, et al: Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121: 509-517.
31. Weber AA, Przytulski B, Schumacher M, et al: Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002; 117: 424-426.
32. Gonzalez-Conejero R, Rivera J, Corral J, et al: Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
33. Morawski W, Sanak M, Cisowski M, et al: Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791-796.
34. A2 polymorphism. Am Heart J 2002; 143: 76-82.
35. Pamukcu B, Oflaz H, Nisanci Y: The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149: 675-680.